Expert Illustrations & Commentaries™: Emerging Strategies for the Treatment of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients
Released On
December 20, 2022
Expires On
December 20, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Nephrology, Transplant Specialists
Topic(s)
Kidney Transplant
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from CSL Behring LLC.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward transplant physicians, transplant surgeons, transplant specialists, and nephrologists. Other clinicians who manage renal transplant patients are invited to participate.
Activity Overview
This Expert Illustrations and Commentaries™ is a video-based program in which 2 experts discuss the etiology and management of antibody-mediated renal transplant rejection. In this activity the faculty focus on the pathophysiology, current and emerging therapeutic strategies for the management of chronic antibody-mediated renal transplant rejection. Their discussion is enriched with the use of video animation to illustrate the pathophysiology of renal transplant rejection and the mechanism of action of emerging agents to prevent rejection. The use of these animated segments helps make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of renal transplant rejection and to improve outcomes for their patients with this disease.
Learning Objectives
- Upon completion of this activity, participants should be better able to:
-
- Describe the mechanisms of chronic active antibody mediated renal transplant rejection (RTR)
- Apply guideline recommendations to the treatment of renal transplant recipients with cABMR
- Assess clinical trial data for emerging and investigational agents to treat cABMR
Faculty
Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Professor of Pediatrics & Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA
Carrie A. Schinstock, MD
Medical Director of Kidney Transplant
Division of Nephrology and Hypertension
Department of Internal Medicine
Associate Professor
Mayo Clinic
Rochester, MN
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
- Stanley C. Jordan, MD, FASN, FAST
-
- Grant/Research Support: CSL Behring, CareDx, Hansa Medical, Vera Therapeutics, Regeneron
- Consultant: CSL Behring, CareDx, Hansa Medical, Vera Therapeutics
- Stock/Shareholder: CSL Behring
- Carrie A. Schinstock, MD
-
- Grant/Research Support: Research Support - CSL Behring
- Consultant: CSL Behring - advisory board
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.